Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hydroxyurea use in patients with sickle cell disease in a Medicaid population.

× No keyword cloud information.

11 in total

1. Greater number of perceived barriers to hydroxyurea associated with poorer health-related quality of life in youth with sickle cell disease.

Authors: Arlene Smaldone; Deepa Manwani; Nancy S Green
Journal: Pediatr Blood Cancer Date: 2019-04-02 Impact factor: 3.167

2. Hydroxyurea Initiation Among Children With Sickle Cell Anemia.

Authors: Sarah L Reeves; Hannah K Jary; Jennifer P Gondhi; Jean L Raphael; Lynda D Lisabeth; Kevin J Dombkowski
Journal: Clin Pediatr (Phila) Date: 2019-05-21 Impact factor: 1.168

3. Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.

Authors: Arlene Smaldone; Sally Findley; Suzanne Bakken; L Adriana Matiz; Susan L Rosenthal; Haomiao Jia; Sergio Matos; Deepa Manwani; Nancy S Green
Journal: Contemp Clin Trials Date: 2016-06-17 Impact factor: 2.226

Review 4. Rigorous and practical quality indicators in sickle cell disease care.

Authors: Suzette O Oyeku; Elissa Z Faro
Journal: Hematology Am Soc Hematol Educ Program Date: 2017-12-08

5. The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease.

Authors: Sarah M Jabour; Sara Beachy; Shayna Coburn; Sophie Lanzkron; Michelle N Eakin
Journal: J Racial Ethn Health Disparities Date: 2019-08-13

6. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.

Authors: Nancy S Green; Deepa Manwani; Mahvish Qureshi; Karen Ireland; Arpan Sinha; Arlene M Smaldone
Journal: Pediatr Blood Cancer Date: 2016-08-30 Impact factor: 3.167

7. Ambulatory quality indicators to prevent infection in sickle cell disease.

Authors: Lauren M Beverung; David Brousseau; Raymond G Hoffmann; Ke Yan; Julie A Panepinto
Journal: Am J Hematol Date: 2014-03 Impact factor: 10.047

8. Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.

Authors: Megan Z Roberts; G Eric Gaskill; Julie Kanter-Washko; T Rogers Kyle; Brittany C Jones; Nicole M Bohm
Journal: J Thromb Thrombolysis Date: 2018-05 Impact factor: 2.300

9. HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol.

Authors: Arlene Smaldone; Deepa Manwani; Banu Aygun; Kim Smith-Whitley; Haomiao Jia; Jean-Marie Bruzzese; Sally Findley; Joshua Massei; Nancy S Green
Journal: BMC Pediatr Date: 2019-10-15 Impact factor: 2.567

Review 10. Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research.

Authors: Scott D Grosse; Nancy S Green; Sarah L Reeves
Journal: Pediatr Blood Cancer Date: 2020-09-17 Impact factor: 3.838